Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities

References

• Chua KB, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000;288:1432–1435. doi: 10.1126/science.288.5470.1432
   PubMed Web of Science ®Google Scholar
• Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis. 2004;10:2082–2087. doi:10.3201/eid1012.040701.
   PubMed Web of Science ®Google Scholar
• Lo MK, Lowe L, Hummel KB, et al. Characterization of Nipah virus from outbreaks in Bangladesh, 2008–2010. Emerg Infect Dis. 2012;18:248–255. doi:10.3201/eid1802.111492.
   PubMed Web of Science ®Google Scholar
• Luby SP, Hossain MJ, Gurley ES, et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001–2007. Emerg Infect Dis. 2009;15:1229–1235. doi:10.3201/eid1508.081237.
   PubMed Web of Science ®Google Scholar
• Sazzad HMS, Hossain MJ, Gurley ES, et al. Nipah virus infection outbreak with nosocomial and corpse-to-human transmission, Bangladesh. Emerg Infect Dis. 2013;19:210–217. doi:10.3201/eid1902.120971.
   PubMed Web of Science ®Google Scholar
• Paul L. Nipah virus in Kerala: a deadly Zoonosis. Clin Microbiol Infect. 2018. doi:10.1016/j.cmi.2018.06.017.
   Web of Science ®Google Scholar
• Satterfield BA, Dawes BE, Milligan GN. Status of vaccine research and development of vaccines for Nipah virus. Vaccine. 2016;34:2971–2975. doi:10.1016/j.vaccine.2015.12.075.
   PubMed Web of Science ®Google Scholar
• Yoneda M, Georges-Courbot M-C, Ikeda F, et al. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One. 2013;8:e58414. doi:10.1371/journal.pone.0058414.
   PubMed Web of Science ®Google Scholar
• Kurup D, Wirblich C, Feldmann H, et al. Rhabdovirus-based vaccine platforms against henipaviruses. J Virol. 2015;89:144–154. doi:10.1128/JVI.02308-14.
   PubMed Web of Science ®Google Scholar
• Lo MK, Bird BH, Chattopadhyay A, et al. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res. 2014;101:26–29. doi:10.1016/j.antiviral.2013.10.012.
   PubMed Web of Science ®Google Scholar
• Weingartl HM, Berhane Y, Caswell JL, et al. Recombinant Nipah virus vaccines protect pigs against challenge. J Virol. 2006;80:7929–7938. doi:10.1128/JVI.00263-06.
   PubMed Web of Science ®Google Scholar
• Middleton D, Pallister J, Klein R, et al. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis. 2014;20:372–379. doi:10.3201/eid2003.131159.
   PubMed Web of Science ®Google Scholar
• Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect. 2001;3:289–295. doi: 10.1016/S1286-4579(01)01382-X
   PubMed Web of Science ®Google Scholar
• Negrete OA, Wolf MC, Aguilar HC, et al. Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog. 2006;2:e7. doi:10.1371/journal.ppat.0020007.
   PubMed Web of Science ®Google Scholar
• Negrete OA, Levroney EL, Aguilar HC, et al. Ephrinb2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature. 2005;436:401–405. doi:10.1038/nature03838.
   PubMed Web of Science ®Google Scholar
• Bonaparte MI, Dimitrov AS, Bossart KN, et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A. 2005;102:10652–10657. doi:10.1073/pnas.0504887102.
   PubMed Web of Science ®Google Scholar
• Aguilar HC, Iorio RM. Henipavirus membrane fusion and viral entry. Curr Top Microbiol Immunol. 2012;359:79–94. doi:10.1007/82_2012_200.
   PubMed Web of Science ®Google Scholar
• Bossart KN, McEachern JA, Hickey AC, et al. Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods. 2007;142:29–40. doi:10.1016/j.jviromet.2007.01.003.
   PubMed Web of Science ®Google Scholar
• Harcourt BH, Lo MK, Roth JA, et al. Development of a neutralization assay for Nipah virus using pseudotype particles. J Virol Methods. 2009;160:1–6. doi:10.1016/j.jviromet.2009.02.025.
   PubMed Web of Science ®Google Scholar
• Noguchi A, Marsh GA, Barr JA, et al. Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase. J Virol Methods. 2012;179:226–232. doi:10.1016/j.jviromet.2011.11.003.
   PubMed Web of Science ®Google Scholar
• Palomares K, Vigant F, Van Handel B, et al. Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J Virol. 2013;87:2094–2108. doi:10.1128/JVI.02032-12.
   PubMed Web of Science ®Google Scholar
• Nie J, Wu X, Ma J, et al. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep. 2017;7:42769. doi:10.1038/srep42769.
   PubMed Web of Science ®Google Scholar
• Liu Q, Fan C, Li Q, et al. Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci Rep. 2017;7:45552. doi:10.1038/srep45552.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Q, Liu Q, et al. A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. Hum Vaccin Immunother. 2017;13:1811–1817. doi:10.1080/21645515.2017.1325050.
   PubMed Web of Science ®Google Scholar
• Li Q, Liu Q, Huang W, et al. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. Vaccine. 2017;35:5172–5178. doi:10.1016/j.vaccine.2017.07.101.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhao C, Liu Q, et al. Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system. Vaccine. 2017;35:6387–6394. doi:10.1016/j.vaccine.2017.10.007.
   PubMed Web of Science ®Google Scholar
• Witting SR, Vallanda P, Gamble AL. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther. 2013;20:997–1005. doi:10.1038/gt.2013.23.
   PubMed Web of Science ®Google Scholar
• de Wit E, Bushmaker T, Scott D, et al. Nipah virus transmission in a hamster model. PLoS Negl Trop Dis. 2011;5:e1432. doi:10.1371/journal.pntd.0001432.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Hickey AC, et al. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One. 2010;5:e10690. doi:10.1371/journal.pone.0010690.
   PubMed Web of Science ®Google Scholar
• Bossart KN, Zhu Z, Middleton D, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009;5:e1000642. doi:10.1371/journal.ppat.1000642.
   PubMed Web of Science ®Google Scholar
• Mungall BA, Middleton D, Crameri G, et al. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol. 2006;80:12293–12302. doi:10.1128/JVI.01619-06.
   PubMed Web of Science ®Google Scholar
• Dhondt KP, Mathieu C, Chalons M, et al. Type I interferon signaling protects mice from lethal henipavirus infection. J Infect Dis. 2013;207:142–151. doi:10.1093/infdis/jis653.
   PubMed Web of Science ®Google Scholar
• Whitt MA. Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods. 2010;169:365–374. doi:10.1016/j.jviromet.2010.08.006.
   PubMed Web of Science ®Google Scholar
• Dups J, Middleton D, Long F, et al. Subclinical infection without encephalitis in mice following intranasal exposure to Nipah virus-Malaysia and Nipah virus-Bangladesh. Virol J. 2014;11:102. doi:10.1186/1743-422X-11-102.
   PubMed Web of Science ®Google Scholar
• Yun T, Park A, Hill TE, et al. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection. J Virol. 2015;89:1242–1253. doi:10.1128/JVI.02583-14.
   PubMed Web of Science ®Google Scholar
• Dups J, Middleton D, Yamada M, et al. A new model for Hendra virus encephalitis in the mouse. PLoS One. 2012;7:e40308. doi:10.1371/journal.pone.0040308.
   PubMed Web of Science ®Google Scholar
• Tamin A, Harcourt BH, Ksiazek TG, et al. Functional properties of the fusion and attachment glycoproteins of Nipah virus. Virology. 2002;296:190–200. doi:10.1006/viro.2002.1418.
   PubMed Web of Science ®Google Scholar
• McEachern JA, Bingham J, Crameri G, et al. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine. 2008;26:3842–3852. doi:10.1016/j.vaccine.2008.05.016.
   PubMed Web of Science ®Google Scholar
• Pallister JA, Klein R, Arkinstall R, et al. Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol J. 2013;10:237. doi:10.1186/1743-422X-10-237.
   PubMed Web of Science ®Google Scholar
• DeBuysscher BL, Scott D, Marzi A, et al. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine. 2014;32:2637–2644. doi:10.1016/j.vaccine.2014.02.087.
   PubMed Web of Science ®Google Scholar
• Prescott J, DeBuysscher BL, Feldmann F, et al. Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. Vaccine. 2015;33:2823–2829. doi:10.1016/j.vaccine.2015.03.089.
   PubMed Web of Science ®Google Scholar
• Walpita P, Cong Y, Jahrling PB, et al. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines. 2017;2:21. doi:10.1038/s41541-017-0023-7.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay A, Rose JK. Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach. J Virol. 2011;85:2004–2011. doi:10.1128/JVI.01852-10.
   PubMed Web of Science ®Google Scholar
• Pallister J, Middleton D, Wang L-F, et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine. 2011;29:5623–5630. doi:10.1016/j.vaccine.2011.06.015.
   PubMed Web of Science ®Google Scholar
• Wong KT, Grosjean I, Brisson C, et al. A golden hamster model for human acute Nipah virus infection. Am J Pathol. 2003;163:2127–2137. doi:10.1016/S0002-9440(10)63569-9.
   PubMed Web of Science ®Google Scholar
• Chen Q, Nie J, Huang W, et al. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. Hum Vaccin Immunother. 2018;14:199–208. doi:10.1080/21645515.2017.1373922.
   PubMed Web of Science ®Google Scholar
• Liu Q, Fan C, Zhou S, et al. Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox. Sci Rep. 2015;5:11397. doi:10.1038/srep11397.
   PubMed Web of Science ®Google Scholar